Search
Innate Pharma SA
IPHAAdd to Watchlist
2.180USD
-0.355-14.00%
Close 08-14 16:00（ET）Quotes delayed by 15 min
202.21MMarket Cap
LossP/E TTM
More Details of Innate Pharma SA Company
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Innate Pharma SA Profile
Ticker SymbolIPHA
Company nameInnate Pharma SA
IPO dateOct 31, 2006
CEODickinson (Jonathan Elliot)
Number of employees181
Security typeDepository Receipt
Fiscal year-endOct 31
Address117 avenue de Luminy
CityMARSEILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code13009
Phone33430303030
Websitehttps://www.innate-pharma.com/
Ticker SymbolIPHA
IPO dateOct 31, 2006
CEODickinson (Jonathan Elliot)
Company Executives of Innate Pharma SA
Name
Name/Position
Position
Shareholding
Change
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mrs. Irina Staatz-Granzer, Ph.D.
Mrs. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Director
Independent Director
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Chief Compliance and Operations Officer, Interim Head of human Resources, Vice President
Chief Compliance and Operations Officer, Interim Head of human Resources, Vice President
--
--
Ms. Odile Laurent
Ms. Odile Laurent
Vice President - Human Resources, Member of the Leadership Team
Vice President - Human Resources, Member of the Leadership Team
--
--
Ms. Pascale Boissel
Ms. Pascale Boissel
Vice Independent Chairman of the Board
Vice Independent Chairman of the Board
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Independent Director, Representative of Bpifrance Participations
Independent Director, Representative of Bpifrance Participations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mrs. Irina Staatz-Granzer, Ph.D.
Mrs. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Director
Independent Director
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
FAQs
Who are the top five shareholders of Innate Pharma SA?
The top five shareholders of Innate Pharma SA are: Mr. Gilles Brisson
How many institutions hold shares of Innate Pharma SA (IPHA)?
As of 2026Q1, 22 institutions hold shares of Innate Pharma SA, with a combined market value of approximately 336.10K, accounting for 0.37% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 136136.00.